Get access to our best features
Get Started
Subscribe
Israeli-Palestinian Conflict
2024 US Election
US Politics
Joe Biden
North American Politics
TikTok
Senate
Donald Trump
US Economy
Republican Party
NFL
Earth Day
US Crime
Get access to our best features
Get Started
Published 1 year ago

Why Adaptimmune (ADAP) Stock Is Plunging Today - TCR2 Therapeutics (NASDAQ:TCRR), Adaptimmune Therapeutics (NASDAQ:ADAP)

Summary by The Business Journals
Adaptimmune Therapeutics, a cell therapy developer with offices in Philadelphia and the United Kingdom, is acquiring TCR² Therapeutics of Cambridge, Massachusetts, in an all-stock transaction. Under the terms of the deal, AdaptImmune (NASDAQ: ADAP) shareholders will own 75% of the combined company. TCR² (NASDAQ: TCRR) stockholders will receive 1.51 Adaptimmune American depository shares for each TCR² share they own, giving them the remaining 25%…

0 Articles

All
Left
Center
Right
The Business JournalsThe Business Journals

Adaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics

Adaptimmune Therapeutics, a cell therapy developer with offices in Philadelphia and the United Kingdom, is acquiring TCR² Therapeutics of Cambridge, Massachusetts, in an all-stock transaction. Under the terms of the deal, AdaptImmune (NASDAQ: ADAP) shareholders will own 75% of the combined company. TCR² (NASDAQ: TCRR) stockholders will receive 1.51 Adaptimmune American depository shares for each TCR² share they own, giving them the remaining 25%…

1 year ago·United States
Read Full Article
BenzingaBenzinga

Why Adaptimmune (ADAP) Stock Is Plunging Today - TCR2 Therapeutics (NASDAQ:TCRR), Adaptimmune Therapeutics (NASDAQ:ADAP)

1 year ago·New York, United States
Read Full Article
Globe NewswireGlobe Newswire

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat...

1 year ago
Read Full Article
Market Wire NewsMarket Wire News

TCRR - Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms.

1 year ago·United States
Read Full Article
Adaptimmune Therapeutics plcAdaptimmune Therapeutics plc

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

1 year ago
Read Full Article
News File CorpNews File Corp

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms

1 year ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

BusinessBusiness
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble Newsletter
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal